Efficacy and safety of low-dose valganciclovir in the prevention of cytomegalovirus disease in adult liver transplant recipients

Authors

  • Jeong M. Park,

    Corresponding author
    1. College of Pharmacy, University of Michigan, Ann Arbor, MI
    2. Department of Pharmacy Services, University of Michigan, Ann Arbor, MI
    • Department of Pharmacy Services, University of Michigan Health System, UH B2 D301 Box 0008, 1500 East Medical Center Drive, Ann Arbor, MI 48109
    Search for more papers by this author
    • Telephone: 734-647-4711; FAX: 734-936-7027

  • Kathleen D. Lake,

    1. College of Pharmacy, University of Michigan, Ann Arbor, MI
    2. Department of Internal Medicine, University of Michigan, Ann Arbor, MI
    Search for more papers by this author
  • Juan D. Arenas,

    1. Department of Surgery, University of Michigan, Ann Arbor, MI
    Search for more papers by this author
  • Robert J. Fontana

    1. Department of Internal Medicine, University of Michigan, Ann Arbor, MI
    Search for more papers by this author

Abstract

The efficacy and safety of valganciclovir (VGCV) for cytomegalovirus (CMV) prophylaxis in liver transplant recipients has not been established. We retrospectively compared the efficacy and safety of low-dose oral VGCV (450 mg once daily for 90 days) and standard oral ganciclovir (1 g three times a day for 90 days, GCV) in preventing CMV disease in 109 adult liver transplant recipients who survived at least 1 month between January 2001 and April 2003 (49 GCV and 60 VGCV). The incidence of CMV disease at 1 year post-transplant was similar among patients treated with VGCV and GCV (3% and 4%, respectively). Three of the four CMV disease cases occurred in high-risk recipients with CMV serotype of donor+/recipient− (D+/R−) and all cases presented after completion of CMV prophylaxis, ranging 114-152 days post-transplant. Severe neutropenia was rare, and thrombocytopenia and anemia occurred at similar frequencies with both prophylaxis regimens. In conclusion, a 90-day regimen of low-dose oral VGCV has a similar efficacy and safety profile to high-dose oral GCV in adult liver transplant recipients. D+/R− liver transplant recipients remain at risk of developing CMV disease after completion of antiviral prophylaxis. Additional prospective studies with close monitoring for CMV viremia and drug resistance are needed to further establish the optimal dose and duration of VGCV in liver transplant recipients. Liver Transpl 12:112–116, 2006. © 2005 AASLD.

Ancillary